Revenue of 35,600 million yen (YoY +1.1%), operating income of 2,700 million yen (YoY +3.5%), and a decrease in interim net income attributable to owners of parent by 213 million yen. Domestic prescription pharmaceuticals and animal health businesses remained solid, while overseas operations saw declines in revenue and profit. Increased R&D expenses offset in part by reductions in certain SG&A items led to higher profit. Consolidated results for the second quarter of the fiscal year ending March 2027 were released.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"ASKA Pharmaceutical Holdings Co.,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4886-20261104-01.pdf","jir_short_summary":"Revenue of 35,600 million yen (YoY +1.1%), operating income of 2,700 million yen (YoY +3.5%), and a decrease in interim net income attributable to owners of parent by 213 million yen. Domestic prescription pharmaceuticals and animal health businesses remained solid, while overseas operations saw declines in revenue and profit. Increased R&D expenses offset in part by reductions in certain SG&A items led to higher profit. Consolidated results for the second quarter of the fiscal year ending March 2027 were released.","jir_summary":"### Overview of Performance\nHighlights show revenue of 35,600 million yen (YoY +1.1%), operating income of 2,700 million yen (YoY +3.5%), ordinary income up 8.5% YoY, and a decrease in interim net income attributable to owners of parent compared with the same period last year. The overall performance was supported by steady trends in domestic prescription pharmaceuticals and the animal health business. Meanwhile, overseas operations experienced declines in both revenue and profit, and increased research and development expenses partially offset by some reductions in selling, general and administrative expenses were contributing factors.\n\n### Outlook and Main Factors\nThe full-year plan sets revenue at 73,000 million yen and operating income at 6,200 million yen. The supplementary materials to the financial summary indicate there are no changes to guidance going forward; despite increased R&D expenses, SG&A improved due to cost reductions such as transportation and storage expenses.","jir_financial_highlights":"Revenue: 35,626 (YoY +1.1%)\nOperating Income: 2,740 (YoY +3.5%)\nOrdinary Income: 2,862 (YoY +8.5%)\nInterim Net Income Attributable to Owners of Parent: 2,006 (YoY -9.6%)\nRevenue (Full-year Plan): 730 (No change)","jir_category":"","jir_hashtags":"#ASKAPharmaceuticalHoldingsCoLtd., #FinancialSummary, #DomesticPrescriptionPharmaceuticals, #AnimalHealth","jir_key_figures":"Revenue: 35,600 million yen (YoY +1.1%)\nOperating Income: 2,700 million yen (YoY +3.5%)\nOrdinary Income: 2,862 million yen (YoY +8.5%)","jir_meta_title":"ASKA Pharmaceutical Holdings Co.,Ltd. - Supplementary Materials to Financial Summary for Q2 FY2027 | Revenue 35,600 million yen, YoY +1.1%","jir_meta_description":"Supplementary materials to the Q2 financial summary for ASKA Pharmaceutical Holdings Co.,Ltd. Revenue 35,600 million yen, operating income 2,700 million yen, ordinary income 2,800 million yen, interim net income attributable to owners of parent decreased by 213 million yen. Includes segment trends and R&D expenditure status.","jir_og_title":"ASKA Pharmaceutical Holdings Co.,Ltd. - Supplementary Materials to Financial Summary for Q2 FY2027","jir_og_description":"Domestic pharmaceuticals and animal health were solid while overseas operations saw declines. R&D expenses increased while SG&A was reduced.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[35253,35626]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[2648,2740]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Interim Net Income Attributable to Owners of Parent Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-3\\\",\\\"2027-3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Interim Net Income\\\",\\\"data\\\":[2219,2006]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Prescription Pharmaceuticals\\\",\\\"Animal Health\\\",\\\"Overseas Operations\\\",\\\"Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[29615,4125,1798,87]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Sales Margin\\\",\\\"SG&A Ratio\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Rate\\\",\\\"data\\\":[\\\"?\\\",\\\"?\\\"]}]},\\\"options\\\":{}}\"}]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141156","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n